AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2021
Aug 9, 2021
31801_dirs_2021-08-09_f91b582e-e228-4504-8565-52d807ed872d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-08-05
Reporting Person: Marucci Anthony S (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-05 | Common Stock | M | 3537 | $42.00 | Acquired | 27231 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-05 | Incentive Stock Option | $42.00 | M | 3537 | Disposed | 2021-08-05 | Common Stock (3537) | Direct |
Footnotes
F1: Includes 4,256 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Option Plan. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2: This option was previously reported as covering 180,400 shares at an exercise price of $2.80 per share, but has been adjusted to reflect the Reverse Stock Split. The remaining 8,488 shares of common stock underlying the option expired on August 5, 2021.
F3: As of August 5, 2015, the option is fully vested.